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Research
AbstrACt
Objective To evaluate the added predictive accuracy of 
bone mineral density (BMD) to fracture risk assessment.
Design Prospective cohort study using data between 01 
January 2010 and 31 December 2012.
setting North Denmark Osteoporosis Clinic of referred 
patients presenting with at least one fracture risk factor to 
the referring doctor.
Participants Patients aged 40–90 years; had BMD 
T-score recorded at the hip and not taking osteoporotic 
preventing drugs for more than 1 year prior to baseline.
Main outcome measures Incident diagnoses of 
osteoporotic fractures (hip, spine, forearm, humerus and 
pelvis) were identified using the National Patient Registry 
of Denmark during 01 January 2012–01 January 2014. 
Cox regression was used to develop a fracture model 
based on predictors in the Fracture Risk Assessment Tool 
(FRAX®), with and without, binary and continuous BMD. 
Change in Harrell’s C-Index and Reclassification tables 
were used to describe the added statistical value of BMD.
results Adjusting for predictors included in FRAX®, 
patients with osteoporosis (T-score ≤−2.5) had 75% higher 
hazard of a fracture compared with patients with higher 
BMD (HR: 1.75 (95% CI 1.28 to 2.38)). Forty per cent 
lower hazard was found per unit increase in continuous 
BMD T-score (HR: 0.60 (95% CI 0.52 to 0.69)). Accuracy 
improved marginally, and Harrell’s C-Index increased 
by 1.2% when adding continuous BMD (0.76 to 0.77). 
Reclassification tables showed continuous BMD shifted 
529 patients into different risk categories; 292 of these 
were reclassified correctly (57%; 95% CI 55% to 64%). 
Adding binary BMD however no improvement: Harrell’s 
C-Index decreased by 0.6%.
Conclusions Continuous BMD marginally improves 
fracture risk assessment. Importantly, this was only 
found when using continuous BMD measurement for 
osteoporosis. It is suggested that future focus should be 
on evaluation of this risk factor using routinely collected 
data and on the development of more clinically relevant 
methodology to assess the added value of a new risk 
factor.
IntrODuCtIOn   
Osteoporosis causes over 8.9 million frac-
tures worldwide, of which over 4.5 million 
occur in the USA and Europe and account 
for 2.8 million disability adjusted life years.1 
Further, 1.2 million disability adjusted life 
years are accounted for by hip fractures, 
which are projected to increase to 6 million 
by 2050.2 
Given this burden, and treatment options 
for osteoporosis, identifying patients at risk 
of an osteoporotic fracture is high priority 
among health policy-makers to reduce the 
risk of future fracture.3 Risk prediction tools 
have been developed to aid in the identifi-
cation of patients at risk. For example, the 
Fracture Risk Assessment Tool (FRAX) and 
QFracture are commonly used to assess frac-
ture risk in patients based on predefined risk 
factors.
Bone mineral density (BMD), a measure-
ment used to aid diagnosis of osteoporosis, 
has also been identified as a fracture risk 
factor.4–7 Unlike some other fracture risk 
factors, treatment options (eg, bisphospho-
nate medication) are available that reduces 
the fracture risk markedly when treatment is 
initiated based on low BMD.
strengths and limitations of this study
 ► Addresses a research question recommended by 
The National Institute for Health and Care Excellence 
to investigate the added value of bone mineral den-
sity (BMD) to fracture risk prediction.
 ► Investigates BMD in both the commonly used, binary 
and continuous format.
 ► Presents changes in calibration, discrimination and 
reclassification to describe the added value of BMD.
 ► Uses robustly collected data from Northern Denmark, 
with 3.2% missing data.
 ► As data are from a North Danish population, with at 
least one fracture risk factor, this limits generalis-
ability of the results.
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English national guidelines (The National Institute 
for Health and Care Excellence (NICE)) for fracture 
risk assessment recommend treatment of osteoporosis to 
prevent fractures but have not included BMD as a manda-
tory risk factor for fracture risk prediction tools to incor-
porate.8 This is partly due to the lack of robust evidence 
and limited generalisability of current research, which 
has particularly focused on evaluating BMD in postmeno-
pausal women when evaluating the added value of BMD 
to existing fracture risk factors.5–7
NICE also recognises this gap in the evidence and have 
recommended research to assess the added value of BMD 
as a risk factor in fracture risk assessment.9
The aim of this study is to assess the value of BMD 
measurement in addition to the standard fracture risk 
factors used in the FRAX risk model using a robustly 
collected prospective cohort.
MethODs
This paper has been written in accordance to the Trans-
parent reporting of a multivariable prediction model for 
individual prognosis or diagnosis (TRIPOD) checklist.
Patient and public involvement
Patients and the public were not involved in the develop-
ment of this research question and were not involved in 
the design of this study.
study design and data source
A prospective cohort study was conducted using patients 
from the Aalborg University Hospital Record for Oste-
oporosis Risk Assessment (AURORA) dataset; patients 
were followed up using the National Patient Registry of 
Denmark.
The AURORA dataset consists of patients attending the 
Osteoporosis Clinic at Aalborg University Hospital after 
a referral from their primary care physician. A referral 
was offered to patients with at least one risk factor for 
osteoporosis (low body mass index (BMI), previous 
fracture, parental hip fracture, smoking status, alcohol 
consumption, glucocorticoid use, rheumatoid arthritis 
and secondary osteoporosis) or if they were aged 80 
years and above. Further detail of the data collection 
has been described elsewhere.10 The Danish National 
Patient Registry which collects inpatient and outpatient 
data from all Danish hospitals was linked to the AURORA 
dataset through unique patient identifiers.
Ethics approval was given through the Region of North 
Jutland’s from the Danish Data Protection Agency (‘para-
plyanmeldelse 2008-58-0028’).
Cohort selection
Data collection for AURORA began 01 January 2010 
and was collected for 3 years (up to 31 December 2012). 
Patients were included if they were aged 40–90 years; 
had a BMD T-score at the hip and were not taking any 
osteoporotic preventing drugs or any bone sparing drugs 
for more than 1 year prior to baseline.
Primary outcome
The primary outcome measure was an incident osteo-
porotic fracture during follow-up (01 January 2012 to 
01 January 2014), defined as a diagnosis of a fracture at 
the hip, spine, forearm, humerus and pelvis. Fractures 
at these sites resulting from traffic, work and sports-re-
lated accidents were excluded from the study. Relevant 
fractures were identified in the Danish National Patient 
Registry, using the International Statistical Classification 
of Diseases, 10th Revision codes (ICD-10 codes), which 
was developed using recognised database methodology 
for each fracture.11
Fracture risk factors
Fracture risk factors, used in the FRAX risk prediction 
model, were extracted at baseline. They were: age; gender; 
height (m); weight (kg); previous fracture; parental history 
of hip fracture, current smoking status; current alcohol 
consumption; glucocorticoid use (currently exposed for 
3+ months); rheumatoid arthritis and secondary osteopo-
rosis (includes type 1 diabetes, osteogenesis imperfecta in 
adults, untreated long-standing hyperthyroidism, hypo-
gonadism, premature menopause (<45 years), chronic 
malnutrition, malabsorption and chronic liver disease).
bMD
Dual-energy X-ray absorptiometry (DEXA) scans were 
performed by trained technicians using Hologic Discovery 
A (Bedford, Massachusetts, USA). A daily quality control 
programme was in place and in vivo coefficient of varia-
tion using repositioning of patients was <1%. Total hip 
BMD was used as region of interest. BMD was added to 
the fracture risk prediction model twice, first, as a contin-
uously measured T-score value, and second, as a binary 
risk factor, dichotomised at/above T-score threshold for 
osteoporosis and below threshold, −2.5 in T-score (manu-
facturers’ normal range using normal material from T 
Kelly et al12) based on WHO classifications.13 Calculated 
T-scores were gender specific.
statistical analysis
A complete case analysis was performed on the data; 3.2% 
of data were missing. The AURORA dataset was split into 
two using recognised methodology14; where a random 
number was assigned to patients and based on a cut-off, 
two-thirds was used to derive the risk models, and the 
remaining third was used to validate them.
Model derivation
Three Cox proportional hazards models were developed 
for the primary outcome, using a complete case analysis 
on the derivation dataset:
Model 1. Standard fracture risk factors only (without 
BMD).
Model 2. Standard fracture risk factors (with binary 
BMD).
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Model 3. Standard fracture risk factors (with contin-
uous BMD).
Graphical methods were used (log–log plots) to assess 
the proportional hazards assumption, and risk factors 
violating this assumption were added to the model as a 
time varying covariate.
Recognised methodology used in research studies was 
used to build the three risk prediction models15 16; the 
Kaplan-Meier method was used to obtain 4-year fracture 
risk estimates for patients. Further detail on the conver-
sion of the Cox proportional hazards models to risk 
prediction models has been provided in online supple-
mentary table 1.
Validation of models
Four-year fracture risk was calculated from each model 
and the predictive performance of each risk prediction 
model was assessed by measures describing calibration, 
discrimination and reclassification. These metrics were 
assessed using the validation cohort.
Calibration measures how well the predicted risk agrees 
with observed risk in the data. It plots the mean predicted 
and observed risk of fracture for each decile of predicted 
risk. The observed risk of fracture was derived from the 
4-year Kaplan-Meier estimate. Good calibration indicates 
the predicted risk is close to the observed risk of the 
outcome.
Discrimination measures how well the risk prediction 
model differentiates between patients who have or have 
not observed the event in the study. This was quantified 
by the area under the receiver operating characteristic 
curve , given by Harrell’s C-Index with higher values indi-
cating better discrimination.
Reclassification tables17 measure movement between 
risk categories when adding a new risk factor. Threshold 
for treatment at 4 years was set at a fracture risk level of 
8.5%; to be comparable to the treatment threshold of 
20% at 10 years. This was presented by the total per cent 
of patients reclassified (incorrectly and correctly) and also 
the Net Reclassification Index (NRI).18 19 The NRI gives 
the net calculation of the changes in the right direction 
and a higher NRI indicates a better reclassifying model.
All analyses were carried out using Stata V.12.20
results
Characteristics of the data
The AURORA collected data on 7912 patients; 1795 
patients were excluded comprising, 440 not aged 
between 40 and 90 years at baseline; 156 not having a 
recorded T-score value for the total hip at baseline and 
1199 patients were taking antiosteoporotic drug therapy 
for more than 1 year prior to baseline.
The study sample consisted of 6117 patients; predom-
inantly female (79.6%) and patients with a mean age of 
62.9 (SD: 10.9) years. Two-thirds of this sample (n=4093) 
was used for the derivation dataset and one-third (n=2094) 
was used for the validation dataset. Table 1 presents the 
baseline characteristics of the study by derivation and 
validation dataset and shows little difference between the 
datasets.
Patients in the derivation dataset had a median 
follow-up time of 2.30 years [IQR:1.57, 2.99] and observed 
318 (7.8%) osteoporotic fractures during follow-up. Of 
these, 316 fractures were eligible for the analysis (two 
patients had a fractures on or prior to baseline and were 
excluded). Patients contributed 9352.8 person-years of 
observation, giving a total incidence rate of 337.87 per 
10 000 person-years (95% CI 302.60 to 377.25).
Fractures during follow-up were predominantly found 
in the forearm (27.0%) and hip (17.9%). Higher frac-
ture incidence rates were found in patients classed as 
osteoporotic, based on their T-score at both the total 
hip (809.73 per 10 000 person-years (95% CI 641.68 to 
1021.78)) and spine (L1-L4) (553.59 per 10 000 person-
years (95% CI 462.55 to 662.55)) (see online supplemen-
tary table 2).
Model development
The unadjusted analysis showed statistically significant 
association between BMD (continuous and binary) and 
osteoporotic fracture (HR=0.55; 95% CI 0.50 to 0.61, 
p<0.001, HR=2.79; 95% CI 2.11 to 3.67, p<0.001, respec-
tively). Significant associations with fracture were also 
found with age (HR=1.03; 95% CI 1.02 to 1.04, p<0.001), 
previous fracture (HR=3.38; 95% CI 2.69 to 4.24, p<0.001), 
BMI (HR=0.97; 95% CI 0.95 to 1.00, p=0.03) and gender 
(HR=0.73; 95% CI 0.53 to 1.00, p=0.05). Further, a time-
varying effect was found in patients with a previous frac-
ture; hazard of a subsequent fracture was highest in the 
first year during follow-up and decreased per year of 
follow-up (p<0.001).
The adjusted analysis is presented in table 2. Model 1 
showed that of the standard risk factors, age and previous 
fracture were significantly associated with fracture; 
hazard of fracture increased by 2% per year increase in 
age (HR=1.024; 95% CI 1.013 to 1.036) and increased 
almost fivefold in patients with a previous fracture at time 
0 years (HR=4.881; 95% CI 3.336 to 7.078).
Hazard of fracture increased by 75% for patients classed 
as osteoporotic by their BMD score (Model 2, HR=1.745; 
95% CI 1.279 to 2.381). Hazard of fracture also decreased 
by 40% per SD improvement in BMD T-score (Model 3, 
HR=0.600; 95% CI 0.524 to 0.686).
Model validation
The 4-year predicted risk of fracture was calculated for 
all patients in the validation dataset; this was compared 
with the observed fracture outcome within the 4-year 
follow-up.
Calibration and discrimination
Calibration plots suggested some improvement when 
adding BMD measurement; particularly when including 
continuous BMD T-score measurement (Model 3; 
see online supplementary figure 1).
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The largest change in discrimination was found when 
adding continuous BMD measurement to standard risk 
factors; Harrell’s C-Index increased by 1.17% (table 3). 
However, binary BMD measurement, as a measure for 
osteoporotic patients, was found to reduce Harrell’s 
C-Index by −0.65%.
reclassification
Reclassification tables indicated that adding continuous 
BMD measurement may improve classification of patients 
into their correct risk categories. This was not found 
when adding binary BMD. Table 4 presents the reclassi-
fication table for Model 1 (standard fracture risk factors 
Table 1 Baseline characteristics of the derivation and 
validation datasets, including missing data
Characteristic 
Derivation 
(n=4093)
Validation 
(n=2024)
No. % No. %
 Gender 
  Female 3266 79.8 1602 79.2 
  Male 827 20.2 422 20.8
Osteoporotic status 
(based on UK guidelines) 
  Normal 1886 46.1 927 45.8
  Osteopaenic 1797 43.9 893 44.1
  Osteoporotic 410 10.0 204 10.1
Previous fracture 
  No 2935 71.7 1423 70.3
  Yes 1158 28.3 601 29.7
No. of previous fractures 
  None 2935 71.7 1423 70.3
  1 fracture 862 21.1 467 23.1
  2–4 fractures 270 6.6 122 6.0
  5+ fractures 26 0.6 12 0.6
Parental history of hip 
fracture 
  No 2755 67.3 1359 67.1
  Yes 1338 32.7 665 32.9
Current smoking status 
  Other (non/ex) 3182 77.7 1529 75.5
  Smoker 911 22.3 495 24.5
Alcohol consumption 
  ≤3 units per day 3875 94.7 1923 95.0
  >3 units per day 218 5.3 101 5.0
Glucocorticoid use 
  No 3577 87.4 1741 86.0
  Yes 516 12.6 283 14.0
Rheumatoid arthritis 
  No 3686 90.1 1801 88.0
  Yes 407 9.9 223 11.0
Other bone affecting 
disease 
  No 2382 58.2 1139 56.3
  Yes 1711 41.8 885 43.7
Secondary osteoporosis 
  No 3438 84.0 1689 83.4
  Yes 655 16.0 335 16.6
By disease
Type 1 diabetes
  No 4010 98.0 1981 97.9 
  Yes 83 2.0 43 2.1
Continued
Characteristic 
Derivation 
(n=4093)
Validation 
(n=2024)
No. % No. %
Osteogenesis
  No 4093 100 2024 100 
  Yes 0 0 0 0
Hyperthyroidism
  No 4089 99.9 2023 99.9 
  Yes 4 0.1 1 0.1
Malnutrition
  No 4090 99.9 2023 99.9 
  Yes 3 0.1 1 0.1
Chronic liver disease
  No 4006 97.9 1979 97.8 
  Yes 87 2.1 45 2.2
Menopause (women 
only)†
  No 853 26.1 405 25.3 
  Yes 2413 73.9 1197 74.7
Premature menopause 
(<45 years)‡
  No 1904 78.9 941 78.6 
  Yes 509 21.1 256 21.4
Mean SD Mean SD
Age (years) 62.9 10.9 63.0 11.0
Weight (kg) 72.1 15.5 72.2 15.9
  Missing 47 1.2 12 0.6
Height (m) 1.7 0.1 1.7 0.1
  Missing 131 3.2 61 3.0
BMI 26.4 5.0 26.4 5.1
  Missing 135 3.3 63 3.1
Hip DEXA T-score −1.1 1.1 −1.2 1.1
†Proportion out of respective number of women.
‡Proportion out of respective number of women with menopause.
BMI, body mass index; DEXA, dual-energy X-ray absorptiometry.
Table 1 Continued 
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only) and Model 3 (standard risk factors with continuous 
BMD), using the 8.5% prespecified risk threshold.
Of the 1960 patients in the validation dataset, 27% 
(n=529) were reclassified into a different risk category 
when including continuous BMD into fracture risk predic-
tion. Two per cent (9/529) were found to be reclassified 
correctly into a higher risk group and 55% (292/529) 
were reclassified correctly into a lower risk group; indi-
cating 22% (292/1342) of patients at high risk in Model 
1, not accounting for BMD measurement, were no longer 
at high risk. The net reclassification improvement when 
adding continuous BMD to standard risk factors, was 
0.03, which resulted from increased specificity (non-event 
NRI=4%) and decreased sensitivity (event NRI=−1%) 
from Model 1 (table 5).
DIsCussIOn
summary of findings
BMD showed significant association with fracture risk 
with a 40% decrease for each SD rise in BMD. However, 
this resulted in small improvements in calibration, 
Table 3 Harrell’s C-Index for models 1, 2, and 3
Model Harrell's C-Index
Change in Harrell’s 
C-Index (% change)*
Model 1: Standard fracture risk factors only (without BMD) 0.764 (0.718 to 0.810) –
Model 2: Standard fracture risk factors only (with binary BMD) 0.759 (0.712 to 0.806) −0.005 (-0.65%)
Model 3: Standard fracture risk factors only (with continuous BMD) 0.773 (0.732 to 0.814) 0.009 (1.17%)
*All change is measures against Model 1.
BMD, bone mineral density.
Table 2 Multivariable analysis for osteoporotic fracture in the derivation cohort. Data are adjusted HRs and 95% CIs
Risk factor 
Adjusted HR (95% CI)
Model 1: standard risk 
factors only
Model 2: standard risk 
factors+BMD (categorical)
Model 3: standard risk 
factors+BMD (continuous)
Age (years) 1.024 (1.013 to 1.036) 1.019 (1.007 to 1.031) 1.007 (0.995 to 1.019)
Gender Female Ref Ref Ref
Male 0.754 (0.544 to 1.044) 0.796 (0.573 to 1.104) 0.851 (0.613 to 1.181)
BMI 0.978 (0.954 to 1.002) 0.989 (0.965 to 1.013) 1.027 (1.000 to 1.055)
Previous fracture No Ref Ref Ref
Yes (time=0
years)
4.881 (3.336 to 7.078) 4.667 (3.214 to 6.778) 4.018 (2.763 to 5.842)
Parental history of hip 
fracture
No Ref Ref Ref
Yes 1.079 (0.834 to 1.397) 1.096 (0.847 to 1.419) 1.105 (0.854 to 1.430)
Current smoker No Ref Ref Ref
Yes 1.121 (0.852 to 1.475) 1.076 (0.817 to 1.417) 1.019 (0.774 to 1.342)
Alcohol consumption 
(>3 units/day)
No Ref Ref Ref
Yes 1.414 (0.904 to 2.212) 1.440 (0.921 to 2.252) 1.459 (0.932 to 2.283)
Glucocorticoid use No Ref Ref Ref
Yes 1.080 (0.753 to 1.550) 1.052 (0.733 to 1.510) 1.038 (0.724 to 1.489)
Rheumatoid arthritis No Ref Ref Ref
Yes 1.098 (0.731 to 1.650) 1.089 (0.725 to 1.637) 1.116 (0.742 to 1.678)
Secondary osteoporosis No Ref Ref Ref
Yes 0.993 (0.729 to 1.354) 0.966 (0.708 to 1.317) 0.911 (0.667 to 1.243)
Osteoporotic No Ref Ref Ref
Yes – 1.745 (1.279 to 2.381) – 
Hip DEXA T-score (SD) – – 0.600 (0.524 to 0.686)
Previous fracture (TVC*) 0.635 (0.489 to 0.826) 0.639 (0.492 to 0.830) 0.644 (0.495 to 0.837)
Data are adjusted HRS and 95% CIs.
*TVC, value is interaction effect and 95% CI.
BMD, bone mineral density; BMI, body mass index; DEXA, dual-energy X-ray absorptiometry; TVC, time-varying covariate.
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discrimination and reclassification. The C-index esti-
mate was slightly higher with continuous BMD, but this 
increase is not conclusive given the width of the CIs. 
Despite the limited improvement found of 1% in discrim-
ination when adding continuous BMD, reclassification 
tables showed 57% of reclassified patients moving into 
their correct risk group through improved specificity. 
Importantly, no improvement was found when adding 
BMD in a binary format.
Our findings are consistent with and corroborate with 
current literature.7 21 22 Specifically, a study conducted in 
the Netherlands with 4-year follow-up, investigating the 
added value of BMD for hip fractures risk, found modest 
improvement in predictability.21 Further, two more recent 
studies also indicated limited added value of BMD to frac-
ture risk prediction.7 22
strengths and limitations
Answering evidence gap
To our knowledge, this is the first study to investigate the 
added value of BMD in a binary and continuous format 
to standard fracture risk factors. Further, it is based on a 
larger sample size than other studies investigating BMD 
in addition to FRAX®.7 21 22 It helps inform the NICE 
research recommendation to assess the added value 
of BMD to routine fracture risk assessment in primary 
care.23 It further highlights that the more commonly used 
for treatment decision-making, binary format of BMD 
resulted in a loss of predictability in fracture risk predic-
tion based on comparable measures for discrimination 
and reclassification.
Robustness of data
The prospective cohort was well populated with key 
standard risk factors recorded: BMI, smoking status and 
alcohol consumption and personal and parental frac-
ture history. Other than 3.2% of missing data for BMI, 
in 6117 patients, complete data were collected for all 
risk factors (including BMD T-score recorded at the total 
hip). Further, the cohort was linked to a national robust 
electronic health records. This Danish National Patient 
Registry allowed for outcome fracture to be identified 
and also provided data on the mechanism for the frac-
ture; this helped more accurately phenotype osteoporotic 
fractures.
Generalisability
The generalisability is affected in a few ways. First, the 
findings are based on a Danish cohort. Second, AURORA 
data were collected from patients who presented to their 
doctor with at least one fracture risk factor and were 
referred to the osteoporosis clinic; this led to a biased 
study sample with a higher risk of a fracture and increased 
age. This could overestimate fracture risk among patients 
in a primary care setting.
Methodology
Due to the increased age of the sample, death becomes 
a competing risk. However, information on death was 
not collected and could not be retrieved. This limited 
the analysis of the data as competing risks could not be 
accounted for which may again lead to an overestimation 
Table 4 Risk reclassification table comparing Model 1 (standard fracture risk factors alone) to Model 3 (standard fracture risk 
factors with continuous BMD measurement), using a clinical 8.5% risk cut-off
Model 3: SRF with continuous BMD
Total
Total no.(%) 
reclassified<8.5% ≥8.5%
Model 1: SRF 
without BMD
<8.5% No. 391 227
618
227 (36.7)
% 63.3 36.7
No. of events 5 9
No. of non-events 386 218
Observed event rate 1.3% 4.0%
≥8.5% No. 302 1040
1342
302 (22.5)
% 22.5 77.5
No. of events 10 121
No. of non-events 292 919
Observed event rate 3.3 11.6
Total 693 1267 1960 529 (27.0)
BMD, bone mineral density; SRF, standard risk factors.
Table 5 Summary of NRI for all comparisons between 
developed fracture risk prediction models
Comparison Event NRI Non-event NRI Overall NRI
Model 
1 versus 
model 2
−3.45% 2.09% −0.01
Model 1 
versus model 
3
−0.69% 4.08% 0.03
NRI, Net Reclassification Index.
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of fracture risk.24 However, as an independent study 
primarily assessing the added value of BMD through 
deriving and validating the fracture risk prediction 
models, this bias would be present in both analyses to 
compare derived risk models with and without BMD 
measurement.
The FRAX® risk algorithm has not yet been published, 
therefore FRAX® estimates could not be directly calcu-
lated for the cohort. Instead, the FRAX® risk model was 
recalibrated on the dataset with and without BMD added. 
Further, fracture outcomes in this study included pelvic 
fractures which are increasingly recognised as low-trauma 
fragility fractures 25 and used BMD taken at the total hip 
instead of at the femur neck as it is the gold standard in 
Denmark.26
Internal validation was performed to validate the 
derived risk prediction models. This may lead to overopti-
mistic results of the performance of the risk models.14 To 
account for this limitation, a commonly practised method 
which randomly assigns patients to the derivation and 
validation datasets was used; further, a similar 1:2 ratio 
was also used to split the data.27–29
The study had a 4-year follow-up which is shorter 
than other recognised risk models. To account for this, 
we adapted the 20% clinical risk threshold for 10-year 
fracture estimates to 8.5% for 4-year fracture estimates, 
assuming that risk is constant over time.30 31
Traditional methodology assessing the added value to 
risk factors to existing risk prediction models are criticised 
to be insensitive to change, to lack interpretability.32–35 
This was shown when finding a 1% change in Harrell’s 
C-Index and overlapping CIs between models, limiting 
the interpretability of results. Reclassification analysis was 
thus also used to provide more clinically interpretable 
results.
Clinical implications
The most notable clinical implication is the more routine 
use of BMD measurement for fracture risk assessment. 
Further, evidence suggests continuous BMD adds better 
predictability compared with the binary format.
Future research
Further research is recommended to evaluate the added 
value of BMD to fracture risk prediction, in particular, in 
addition to QFracture risk factors and using primary care 
routinely collected data. However, a brief interrogation 
into the Clinical Practice Research Datalink, a routinely 
collected UK primary care database, showed poor avail-
ability of BMD measurement in patient records, and thus, 
strong limitations to potential analyses. Less than 1% 
of patients had BMD recorded from a sample of 60 658 
patients aged 40–90; not on any osteoporotic treatment 
and with complete data for age, gender, BMI, smoking 
status and alcohol consumption. Thus, prior to UK anal-
ysis, BMD recording in primary care databases needs to 
improve.
Methodologically, as well as assessing the added value of 
BMD to standard risk factors, we should also explore the 
option to replace existing fracture risk factors with the 
BMD measurement; this has rarely been explored in the 
literature but should be considered in future analyses. We 
also recommend research to investigate the added value 
of BMD in a potentially more natural, three-group format 
of BMD (osteopaenic, normal, osteoporotic).
In addition, further research is recommended to 
develop current methodology used to assess the added 
value of BMD to provide more clinically relevant results, 
such as cost implications and to allow for better compara-
bility between new risk factors with respect to their added 
value, thus improving decision-making.
COnClusIOn
Continuous BMD marginally improves fracture risk 
assessment. Importantly, this was only found when using 
continuous BMD measurement for osteoporosis. It seems 
that prediction models for fragility fracture risk may be 
improved only marginally, using present risk factor assess-
ment and evaluations. It is suggested that future focus 
should be on additional risk factors and on the develop-
ment of more clinically relevant methodology to assess 
the added value of a new risk factor.
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